Pull to refresh
Logo
Daily Brief
Following Why Ranks Sign Up
Carmen Guerra

Carmen Guerra

Staff Scientist at CNIO, Co-Senior Author

Appears in 1 story

Notable Quotes

"KRAS inhibitors are yielding better results than chemotherapy, but ultimately resistance appears. That's why we are investigating the molecular mechanism of these resistances."

Stories

The race to drug KRAS in pancreatic cancer

New Capabilities

Named in PNAS retraction for undisclosed financial stake in Vega Oncotargets; paper resubmitted through standard peer review

In April 2026, daraxonrasib became the first drug to beat chemotherapy in a Phase 3 pancreatic cancer trial, cutting death risk by 60% and extending median survival from 6.7 to 13.2 months. The FDA authorized expanded access May 1; Revolution Medicines plans to file a New Drug Application and present full Phase 3 data at the ASCO Annual Meeting on May 31, 2026.

Updated 5 days ago